Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kidney Transplant Failure and Rejection Clear all

Conditions: Kidney Transplantation
Interventions: Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI; Drug · Biological
Lead sponsor: Singulera Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota

Conditions: Kidney Transplant Rejection
Interventions: AT-1501, Tacrolimus; Drug
Lead sponsor: Eledon Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 23 more

Conditions: Renal Failure
Interventions: LCP-Tacro, Prograf; Drug
Lead sponsor: Asahi Kasei Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: End Stage Renal Disease
Interventions: Expanded Tregs; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Transplant; Failure, Kidney
Interventions: Myfortic Escalation; Drug
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Brain Death, Organ Donation, Organ Transplant Failure or Rejection, Delayed Graft Function
Interventions: Pump Eligible - Normothermia - Pump Both Kidneys, Pump Eligible - Hypothermia and Pump Right Kidney, Pump Eligible - Hypothermia and Pump Left Kidney, Not Pump Eligible - Normothermia, Not Pump Eligible - Hypothermia; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 1,427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: Phoenix, Arizona • San Francisco, California • Denver, Colorado + 4 more

Conditions: Transplant;Failure,Kidney, Kidney Transplant, Kidney Rejection Transplant
Interventions: Not listed
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 100 Years
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Transplantation, Kidney Disease, Kidney Failure, Chronic
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 80 Years
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 5
States / cities: Chicago, Illinois • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: End Stage Renal Disease, Renal Transplant
Interventions: Anti-Thymocyte Globulin, TOL101, Steroids, Tacrolimus, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Tolera Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 12
States / cities: Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more

Conditions: End-stage Renal Failure, Kidney Graft Rejection
Interventions: Blood drawing for immune monitoring and questionnaires; Other
Lead sponsor: University of Regensburg; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Kidney Transplant Failure and Rejection
Interventions: immediate-release tacrolimus, extended release tacrolimus; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Transplant;Failure,Kidney, Transplant; Failure, Pancreas, Rejection Acute Renal, Rejection Acute Pancreas
Interventions: dd-cfDNA Blood Test; Diagnostic Test
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Madison, Wisconsin

Conditions: End Stage Renal Disease, Rejection of Renal Transplant
Interventions: Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]; Drug
Lead sponsor: Lorenzo Gallon; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prevention of Rejection in Kidney Transplant
Interventions: AT-1501; Drug
Lead sponsor: Eledon Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Kidney Transplant Rejection
Interventions: AT-1501, Tacrolimus; Drug
Lead sponsor: Eledon Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 26
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 22 more

Conditions: Kidney Transplant Failure and Rejection
Interventions: AlloSure ddcfDNA assay, AlloMap assay, Inflammatory Cytokines, Immune Cell Phenotypes; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: End-stage Renal Disease, Renal Transplantation, Kidney Transplantation
Interventions: Conditioning Regimen; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Rejection of Renal Transplant, Graft Failure
Interventions: Donor-derived cell-free DNA; Diagnostic Test
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Kidney Failure, Chronic
Interventions: Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Kidney Transplantation, Kidney Disease
Interventions: Alemtuzumab, Sirolimus, Tacrolimus, Kidney transplant, Methylprednisolone (or equivalent), Acetaminophen, Diphenhydramine, Trimethoprim (TMP)/Sulfa (Bactrim, Septra), Valgancyclovir, Acyclovir, Pentamidine, Clotrimazole, Nystatin; Drug · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Renal Failure
Interventions: LCP-Tacro tablets, Prograf; Drug
Lead sponsor: Asahi Kasei Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Kidney Transplant Failure and Rejection
Interventions: QSant; Other
Lead sponsor: NephroSant; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Kidney Failure
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 70 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 5
States / cities: Chicago, Illinois • Ithaca, New York • New York, New York + 2 more

Search by objective public record fields.

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients

Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)

Deceased Organ Donor Interventions to Protect Kidney Graft Function

Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients

Urine Testing to Detect Kidney Transplant Rejection

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Reference Group Trial for The ONE Study

Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant

Prospective Assessment of Rejection in Kidney Transplant (PARK)

Immune Monitoring in Sensitized Patients at Risk of Rejection

Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival